Other Mutations: GNA

NCT05340621: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

NCT05340621
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS, BRAF, NF1/2, GNA
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Phase 1b; Patients must have tumor with an activating mutation in the RAS pathway
Exclusions: Patients with prior exposure to histone deacetylases (HDAC) inhibitors, pan-deacetylating agents, or valproic acid for the treatment of cancer; Patients with symptomatic, unstable, untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT05340621

NCT03947385: Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

NCT03947385
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: GNA
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express a GNAQ/11 hotspot mutation
Exclusions: Patients with known symptomatic brain metastases; Patients with prior treatment of a PKC, MEK, ALK, MET, or ROS1 inhibitor; Patients with MSI-H/dMMR tumors who have not previously received immune checkpoint inhibitors
https://ClinicalTrials.gov/show/NCT03947385

Up ↑